2025 United Kingdom Antibodies Market Revenue Opportunities Report
Description
The 2025 United Kingdom Antibodies Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antibody market within the United Kingdom include Amphista Therapeutics, Autolus Therapeutics, Silence Therapeutics, and Merck & Co. Amphista Therapeutics, based in Cambridge, specializes in targeted protein degradation, developing advanced molecular glue therapies for cancer and neurological diseases, backed by significant collaborations such as with Bristol Myers Squibb. Autolus Therapeutics in London is renowned for its CAR-T cell therapies, having achieved FDA approval for a treatment targeting acute lymphoblastic leukemia and pursuing further immuno-oncology innovations. Silence Therapeutics focuses on RNA interference therapies, contributing to cutting-edge genetic medicine development within the UK biopharma sector. Merck & Co., a global biopharmaceutical leader, invests heavily in bispecific antibodies and immuno-oncology, actively expanding its UK presence through advanced antibody research.
These companies leverage the UK's strong biotech ecosystem to advance antibody-based treatment modalities, particularly in oncology and immunology. Autolus and Amphista exemplify the UK’s forefront role in personalized and protein degradation therapies respectively, while Merck brings robust global clinical development and bispecific antibody pipelines targeting cancer and autoimmune diseases. Silence Therapeutics adds RNAi therapeutic strategies, broadening the UK antibody market landscape. Their combined efforts highlight the UK's integral contribution to next-generation antibody therapeutics, supported by strategic partnerships, regulatory approvals, and innovation in biologic medicines expanding the region’s biotech prominence.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antibody market within the United Kingdom include Amphista Therapeutics, Autolus Therapeutics, Silence Therapeutics, and Merck & Co. Amphista Therapeutics, based in Cambridge, specializes in targeted protein degradation, developing advanced molecular glue therapies for cancer and neurological diseases, backed by significant collaborations such as with Bristol Myers Squibb. Autolus Therapeutics in London is renowned for its CAR-T cell therapies, having achieved FDA approval for a treatment targeting acute lymphoblastic leukemia and pursuing further immuno-oncology innovations. Silence Therapeutics focuses on RNA interference therapies, contributing to cutting-edge genetic medicine development within the UK biopharma sector. Merck & Co., a global biopharmaceutical leader, invests heavily in bispecific antibodies and immuno-oncology, actively expanding its UK presence through advanced antibody research.
These companies leverage the UK's strong biotech ecosystem to advance antibody-based treatment modalities, particularly in oncology and immunology. Autolus and Amphista exemplify the UK’s forefront role in personalized and protein degradation therapies respectively, while Merck brings robust global clinical development and bispecific antibody pipelines targeting cancer and autoimmune diseases. Silence Therapeutics adds RNAi therapeutic strategies, broadening the UK antibody market landscape. Their combined efforts highlight the UK's integral contribution to next-generation antibody therapeutics, supported by strategic partnerships, regulatory approvals, and innovation in biologic medicines expanding the region’s biotech prominence.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
